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E-mail address: tsato@saitama-med.ac.jp (T. Sato)Recent studies have indicated that acetylcholine (ACh) plays a vital role in various tissues, while the
role of ACh in bone metabolism remains unclear. Here we demonstrated that ACh induced cell pro-
liferation and reduced alkaline phosphatase (ALP) activity via nicotinic (nAChRs) and muscarinic
acetylcholine receptors (mAChRs) in osteoblasts. We detected mRNA expression of several nAChRs
and mAChRs. Furthermore, we showed that cholinergic components were up-regulated and sub-
units/subtypes of acetylcholine receptors altered during osteoblast differentiation. To our knowl-
edge, this is the ﬁrst report demonstrating that osteoblasts express speciﬁc acetylcholine
receptors and cholinergic components and that ACh plays a possible role in regulating the prolifer-
ation and differentiation of osteoblasts.
Crown Copyright  2010 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction
A growing body of literature has demonstrated that neuronal
factors such as vasoactive intestinal peptide (VIP), calcitonin
gene-related peptide, and substance P directly affect the differenti-
ation of both osteoblasts and osteoclasts and that the sympathetic
nervous system regulates bone remodeling [1–3].
Increasing evidence indicates that acetylcholine (ACh), a well-
known neurotransmitter, is involved in the regulation of basic
functions such as proliferation, differentiation, cell–cell contact,
immune functions, secretion, and absorption in non-neuronal cells
[4,5]. Immune cell function is regulated by its own cholinergic sys-
tem. For example, muscarinic ACh receptors (mAChRs) play a cru-d by Elsevier B.V. on behalf of Fede
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tinic acetylcholine receptors;
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l peptide; BrdU, 5-bromo-20-
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.cial role in the cytokine production and the differentiation of T cells
[6]. In lung, all components needed for an autocrine cholinergic
signaling pathway are expressed in airway bronchial epithelial
cells, and ACh acts as an autocrine growth factor in small cell lung
carcinoma [7,8]. ACh attenuates macrophage activation and de-
creases the production of proinﬂammatory mediators by macro-
phages stimulated with endotoxin [9]. In rodent models of
endotoxemia and hemorrhagic shock, stimulation of the efferent
vagus nerve dampens macrophage activation [5]. In addition, many
non-neuronal cells, including keratinocytes, lymphocytes, placen-
tal trophoblasts, embryonic stem cells, epithelial cells, and endo-
thelial cells, can synthesize ACh and release autocrine or
paracrine hormones [10–12]. Non-neuronal cells that possess cho-
linergic components uptake choline by means of the high afﬁnity
choline transporter (CHT1) and then synthesize ACh by choline
acetyltransferase (ChAT) from choline and acetyl-coenzyme A
(acetyl-CoA). ACh is translocated into small synaptic vesicles by
vesicular ACh transporter (VAChT) and is released via exocytosis.
Once released, ACh exerts its cellular functions via mAChRs, includ-
ing 5 subtypes (M1, M2, M3, M4 and M5), and nicotinic ACh recep-
tors (nAChRs), including 16 subunits (a1, a2, a3, a4, a5, a6, a7, a9,ration of European Biochemical society. All rights reserved.
818 T. Sato et al. / FEBS Letters 584 (2010) 817–824a10, b1, b2, b3, b4, c, d and e). Finally, ACh is rapidly degraded into
choline and acetate by acetylcholinesterase (AChE) [12].
Periosteum, which consists of an outer layer of dense connec-
tive tissue with resident ﬁbroblasts and an inner cellular layer con-
taining immature osteoblasts and osteochondral progenitors,
receives two classes of sympathetic innervation: noradrenergic ﬁ-
bers associated with the vasculature and non-adrenergic VAChT-
and VIP-immunoreactive ﬁbers associated with the parenchyma
[13–15]. Asmus et al. have demonstrated that axons decrease their
expression of catecholaminergic properties and acquire VAChT-
and VIP-immunoreactivity on contact with the periosteum during
development in vivo and after transplantation and that osteoblasts
induce cholinergic function in cultured sympathetic neurons
[16,17].
It is conceivable that VIP and ACh derived from VAChT- and VIP-
immunoreactive ﬁbers affect osteoblasts in the periosteum. Previ-
ous studies have demonstrated that osteoblasts express VIP recep-
tors and that VIP stimulates the activity and mRNA expression of
alkaline phosphatase (ALP) [18–20]. However, it remains unknown
how ACh acts on osteoblasts and whether osteoblasts have cholin-
ergic receptors and components. We hypothesized that ACh plays a
functional role in bone metabolism. In the present study, we inves-
tigated the action of ACh during osteoblastic proliferation and dif-
ferentiation and the mRNA expression of cholinergic receptors and
components for ACh synthesis and release in osteoblasts.2. Materials and methods
2.1. Reagents and antibodies
2-Acetoxy-N,N,N-trimethylethanaminium chloride (ACh), ()-
1-methyl-2-(3-pyridyl) pyrrolidine (+)-bitartrate salt (nicotine;
Nic), (2S,4R,5S)-(4-hydroxy-5-methyl-tetrahydrofuran-2-ylmethyl)-
trimethyl-ammonium chloride (muscarine, Mus), 2-carbamoyloxy-
ethyl-trimethyl-azanium chloride (carbachol, CCh), (8-methyl-8-
azabicyclo[3.2.1]oct-3-yl) 3-hydroxy-2-phenylpropanoate (atro-
pine, Atr), and N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
hydrochloride (mecamylamine, Mec) were obtained from Sigma–
Aldrich. Antibodies against Cdk4 (C-22), Cdk6 (DCS-83), cyclin D1
(HD11) and b-actin (C-4) were obtained from Santa Cruz Biotech-
nologies (California, USA).
2.2. Cell culture
Murine primary osteoblasts (pOB) were isolated from calvarie
taken from newborn ddY mice (SLC, Shizuoka, Japan). The experi-
ments were conducted according to the institutional ethical guide-
lines for animal experiments. Neonatal mouse calvaria were
dissected free of adherent soft tissue, washed in PBS, and sequen-
tially digested with 0.2% dispase and 0.1% collagenase. pOB and the
mouse pre-osteoblastic cell line MC3T3-E1 were maintained in
growthmedium, consisting of a-modiﬁedminimum essential med-
ium (a-MEM) (WAKO, Osaka, Japan) with 10% fetal bovine serum
(FBS) (BioWest, Nuaillé, France). For osteoblastic differentiation as-
say, cells were cultured in growthmedium containing ascorbic acid
(50 lg/ml) and b-glycerophosphate (10 mM) (conditioned med-
ium). The growthmedium and the conditionedmediumwere chan-
ged every three days. All cultures were maintained at 37 C in
humidiﬁed air including 5% CO2 and were passaged every seven days.
2.3. 5-Bromo-20-deoxyuridine (BrdU) incorporation assay
DNA synthesis was assessed with a Cell Proliferation Biotrack
ELISA System (GE Healthcare Life Sciences, Buckinghamshire, UK)
according to manufacturer’s recommendations. This assay mea-sures BrdU incorporation during DNA synthesis by proliferating
cells. Brieﬂy, cells were plated to a density of 5  103 cells/well
in 96-well plates and allowed to proliferate for 24 h. Next, their
growth was arrested by incubation for 24 h in serum-free medium.
Cells were then treated with stimulants (ACh, CCh, Mus, and Nic) at
the indicated doses in growth medium for 60 h. To assess the
effects of inhibitors (Mec and Atr), growth-arrested cells were
treated with growth medium for 60 h plus stimulants in the pres-
ence or absence of inhibitors at the indicated doses, which were
added 1 h before treatment with stimulants. The absorbance was
measured at 450 nm using a Model 680 XR plate reader (BIO
RAD, California, USA). Measurements are represented by the means
of at least three independent experiments, with each data point
based on six replicates.
2.4. Reverse-transcriptase polymerase chain reaction (RT-PCR)
After reaching conﬂuence, cells were incubated in conditioned
medium in the presence or absence of ACh (1nM) for 14 days. Total
RNA (2 lg) was extracted from cells using ISOGEN (Nippon Gene,
Tokyo, Japan) and was subjected to RT-PCR using a SuperScript
One-Step RT-PCR kit (Invitrogen, California, USA) according to
manufacturer’s instructions. The gene-speciﬁc primer pairs used
are shown in Table 1. For RT-PCR analysis, cDNA synthesis was per-
formed for 30 min at 45 C, and the products were denatured for
2 min at 94 C. PCR ampliﬁcation was carried out for 38 cycles
(denaturation for 60 s at 94 C, followed by primer annealing for
90 s at 55 C, and extension for 120 s at 72 C). GAPDH was used
as a loading control.
2.5. Quantitative real time RT-PCR
To validate gene expression changes, quantitative real time RT-
PCR analysis was performed with an Applied Biosystems Prism
7900HT Sequence Detection System according to manufacturer’s
instructions (Applied Biosystems Inc., California, USA) for runx2
and osterix. TaqMan Gene Expression Assays for runx2 (assay iden-
tiﬁcation number Mm00501580_m1) and osterix (assay identiﬁca-
tion number Mm00504574_m1) were inventoried products
(Applied Biosystems Inc.). Mouse GAPDH gene was used as endog-
enous control (assay identiﬁcation number Mm03302249_g1).
After reaching conﬂuence, cells were incubated in conditioned
medium for 14 days. Total RNA (2 lg) was extracted from cells
using ISOGEN (Nippon Gene). Reverse-transcriptase reaction was
performed with the High Capacity RNA-to-cDNA Master Mix (Ap-
plied Biosystems Inc.). The thermal cycler conditions were as fol-
lows: step 1 for 60 min at 37 C and step 2 for 5 min at 95 C.
PCR ampliﬁcation with real-time detection was performed with
TaqMan Gene Expression Master Mix (Applied Biosystems Inc.)
and total RNA of 100 ng/ll. Thermal cycling conditions comprised
an initial UNG incubation at 50 C for 2 min, AmpliTaq Gold DNA
polymerase activation at 95 C for 10 min, 40 cycles of denaturing
at 95 C for 15 s, and annealing and extension at 60 C for 1 min. All
samples were performed in triplicate. Ampliﬁcation data were ana-
lyzed with an Applied Biosystems Prism Sequence Detection Soft-
ware version 2.1 (Applied Biosystems Inc.). To normalize the
relative expression of the genes of interest to the GAPDH control,
standard curves were prepared for each gene mentioned above
and the GAPDH in each experiment.
2.6. Western blot analysis
To detect cyclin D1, cdk4, and cdk6, cells were plated at a den-
sity of 5  105 cells in a 100-mm-diameter dish and allowed to
proliferate for 24 h. Their growth was then arrested by incubation
for 48 h in a-MEM containing 0.5% FBS. Growth-arrested cells were
Table 1
Mouse primers for RT-PCR.
Forward Reverse
a1 TCTCAAGCAAAAAGTGGTCG ATTCCGAGATCTGCCTGTCT
a2 CTCCCATCCTGCTTTCCAG GTTTGAACAGGCGGTCCTC
a3 GTGAATTCTTCAGCCGTGCAGACTCCA ATAAGCTTGGCAACGTACTTCCAATCATC
a4 GTGAATTCCACAGGTCGTACACGGGTCG ATAAGCTTGCGAGCCCGGCATCTTGAGT
a5 AGTGGGGCTGGACCTAAATCTCG CAAAAAGCCCTAAAGTCCCAATGA
a6 CTTTGTCACGCTGTCCAT GCCTCCTTTGTCTTGTCC
a7 ACAGTACTTCGCCAGCACCA AAACCATGCACACCAATTCA
a9 ACAAGGCCACCAACTCCA ACCAACCCACTCCTCCTCTT
a10 TCTGACCTCACAACCCACAA TCCTGTCTCAGCCTCCATGT
b1 TGATGTGGTGCTGCTGAACAA CAACGTCGAAATTTCCGTCAT
b2 GTGAATTCAGGGCGAGGCGGTTTTCTT ATAAGCTTGCGTACGCCATCCACTGCT
b3 GTGAATTCTGGGTGAAGAGGCTGTT ATAAGCTTATCGCTGGCGGGAGTCTGTT
b4 GTGAATTCCATGGCATCCTGGGTCAAG ATAAGCTTCTGGGGAGGCCTGCTGTGT
c GATGCAATGGTGCGACTATCGC GCCTCCGGGTCAATGAAGATCC
d CTGCCAGTCGAA CTGCTGGGAAATCCTAGGCACACTTGAG
e ATTGAAGAGCTTAGCCTGTA TACACCTGCAAAATCGTCCT
M1 GCAGCAGCTCAGAGAGGTCACAG GATGAAGGCCAGCAGGATGG
M2 GCGGATCCTGTGGCCAACCAAGAC CGAATTCACGATTTTGCGGGCTA
M3 AAGGCACCAAACGCTCATCT GCAAACCTCTTAGCCAGCGT
M4 AGCCGCAGCCGTGTTCACAA TGGGTTGAGGGTTCGTGGCT
M5 GTCTCCGTCATGACCATACTCTA CCCGTTGTTGAGGTGCTTCTAC
ChAT CCTGCCAGTCAACTCTAGCC TCAGGGCAGCCTCTCTGTAT
AChE TTGGAGTCTCGAGGGTCATT GGACGAGGGCTCCTACTTTC
VAChT ATGATCGCCGACAAGTATCC CCATTGTGTGCTTCATCC
CHT1 CATCCTCAGCCACCTATGCT TGGATACCCGTAGGCAGTCT
Collagen 1 a1 TTGATCTGTATCTGCCACAA GCTGATTTTTCATCATAGCC
Osteocalcin TGCTTGTGACGAGCTATCAG GAGGACAGGGAGGATCAAGT
GAPDH TGAAGGTCGGTGTGAACGGATTTGGC CATGTAGGCCATGAGGTCCACCAC
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ence or absence of ACh. The analysis was performed as described
previously [21]. Brieﬂy, cells were rinsed with ice-cold PBS and
lysed with a lysis buffer (150 mM NaCl, 50 mM Tris–HCl [pH 8.0],
10 lg/ml aprotinin, 0.1 M NaF, 2 mM Na3VO4, and 1 mM PMSF).
The lysates were incubated on ice for 15 min and centrifuged at
15,000g for 10 min at 4 C. The protein content was quantiﬁed
by the Lowry method (BIO RAD). Equal amounts of proteins were
separated by SDS–polyacrylamide gel electrophoresis and electro-
transferred to polyvinylidene diﬂuoride membranes (BIO RAD).
After the blocking of nonspeciﬁc binding by soaking the ﬁlters in
5% skim milk (Sigma–Aldrich), the desired proteins were immuno-
detected with their respective antibodies, followed by visualization
with the use of an ECL Plus Western blotting detection system (GE
Healthcare), according to manufacturer’s instructions. The bands
were scanned with a LAS-3000mini luminescent image analyzer
(Fuji Film, Tokyo, Japan). b-Actin was used as a loading control.
2.7. Measurement of ALP activity
Cells were plated at a density of 2  104 cells in 24-well plates.
After reaching conﬂuence, cells were incubated in conditioned
medium with stimulants (ACh, CCh, Mus, and Nic) at the indicated
doses for seven days. To assess the effects of inhibitors (Mec and
Atr), cells were pre-treated with inhibitors at the indicated doses,
which were added 1 h before treatment with stimulants. The ALP
activity was assayed (Wako) as described previously [22] and nor-
malized by the amount of protein, determined using the Lowry
method (BIO RAD). The measurements are expressed as the means
of at least three independent experiments, with each data point
based on four replicates.
2.8. Statistical analysis
The data are presented as means ± S.D. Statistical signiﬁcance
was assessed by Student’s t-test using SPSS 14.0J. Differences were
considered to be signiﬁcant at P < 0.05.3. Results
3.1. ACh, CCh, Nic, and Mus induce cell proliferation via AChRs in
osteoblasts
Since we previously showed that Nic, an agonist of nAChRs, in-
duced proliferation of osteoblasts [23], we examined whether CCh
(an analog of ACh) at the indicated doses promoted S phase entry
in MC3T3-E1, assessed by BrdU incorporation assay. CCh signiﬁ-
cantly increased the osteoblast proliferation rate (Fig. 1A). We ana-
lyzed the effects of ACh, CCh, and antagonists such as Mec and Atr.
ACh and CCh signiﬁcantly induced cell proliferation, and the prolif-
erative effects of ACh and CCh were abrogated by the nAChRs and
mAChRs antagonists Mec and Atr (Fig. 1B and C). We then tested
whether Nic and Mus promoted S phase entry via each receptor
in MC3T3-E1. Nic and Mus signiﬁcantly induced cell proliferation,
and the proliferative effects of Nic and Mus were abrogated by Mec
and Atr (Fig. 1D).
Next, we examined whether these drugs could promote cell
proliferation in murine pOB. ACh, Nic, and Mus signiﬁcantly in-
duced cell proliferation, and the proliferative effects of ACh, Nic,
and Mus were abrogated by Mec and Atr in pOB (Fig. 1E and F).
These results suggest that agonists of AChRs promote S phase entry
in murine osteoblasts.
3.2. ACh up-regulates cyclin D1 expression in MC3T3-E1 cells
Next, we studied the role of signal transduction in the prolif-
erative effects of ACh. Since Nic up-regulates cyclin D1 expres-
sion in MC3T3-E1 [23], the contributions of cyclin D1, cdk4,
and cdk6 were examined by Western blot analysis. The expres-
sion of cdk4 and cdk6 did not change during serum stimulation
in the presence or absence of ACh. The amount of cyclin D1
showed little change until 48 h in the absence of ACh, but in-
creased dramatically until 48 h in the presence of ACh (Fig. 2).
These results suggest that ACh promotes cell cycle progression
by up-regulating cyclin D1.
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Fig. 1. Agonists of AChRs induce cell proliferation in osteoblasts. We used MC3T3-E1 in (A–D) and pOB in (E) and (F). (A) Cells were treated with CCh at various concentrations
(1 nM, 1 lM, 1 mM). (B) Cells were treated with 1 nM CCh in the presence or absence of Mec (1 lM) or Atr (1 lM). (C) Cells were treated with 1 nM Nic or 1 nM Mus in the
presence or absence of Mec (1 lM) or Atr (1 lM). (D) Cells were treated with 1 nM ACh in the presence or absence of Mec (1 lM) or Atr (1 lM). (E) Cells were treated with
1 nM Nic or 1 nM Mus in the presence or absence of Mec (1 lM) or Atr (1 lM). (F) Cells were treated with 1 nM ACh in the presence or absence of Mec (1 lM) or Atr (1 lM).
Error bars represent ± S.D. *P < 0.05 as compared with control.
820 T. Sato et al. / FEBS Letters 584 (2010) 817–8243.3. ACh, CCh, and Mus reduced ALP activity in osteoblasts
We previously reported that Nic reduced ALP activity [23]. We
therefore investigated whether ACh, CCh, and Mus directly affect
ALP activity in MC3T3-E1 cultured in conditioned medium. As
shown in Fig. 3A, ALP activity in MC3T3-E1 was signiﬁcantly re-
duced by Nic and Mus in dose-dependent manners on day 7. ACh
also reduced ALP activity, and the inhibitory effect of ACh was
abrogated by the nAChRs and mAChRs antagonists Mec and Atr
in MC3T3-E1 on day 7 (Fig. 3B). In pOB, CCh reduced ALP activity
on day 7 (Fig. 3C). We also tested whether ACh could reduced min-eralization, but ACh had no effect (data not shown). Thus, our data
indicate that agonists of AChRs reduced ALP activity in osteoblasts.
3.4. AChE, VAChT, ChAT, and CHT1 mRNAs were detected in osteoblasts
Next, we examined the mRNA expression of cholinergic compo-
nents such as AChE, VAChT, ChAT, and CHT1 during osteoblastic
differentiation. To conﬁrm osteoblastic differentiation, we ana-
lyzed the expression of osteogenic markers, such as osteocalcin,
runx2 and osterix. We detected up-regulation of osteocalcin mRNA
during osteoblastic differentiation, while col1a1 and GAPDHmRNA
ACh 1nM
0 24 36
control
h 48 24 36 48
cyclin D1
cdk4
cdk6
β-actin
Fig. 2. ACh induces cyclin D1 expression in MC3T3-E1. Growth-arrested MC3T3-E1
cells were stimulated with serum in the presence or absence of 1 nM ACh. Cell
lysates were collected at 24, 36, and 48 h.
T. Sato et al. / FEBS Letters 584 (2010) 817–824 821showed little change by RT-PCR (Fig. 4A). We also detected signif-
icant up-regulation of runx2 and osterix mRNA during osteoblastic
differentiation using real time RT-PCR (Fig. 4B).
As shown in Fig. 4C, AChE, VAChT, ChAT, and CHT1 mRNAs were
detected in both immature and mature osteoblasts. CHT1 mRNA
was expressed in murine pOB, but not in MC3T3-E1. Moreover,
pOB showed slightly increased mRNA expression of AChE, VAChT,
ChAT, and CHT1. These results suggest that the production of
cholinergic components is increased during osteoblastic
differentiation.(%
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Fig. 3. Agonists of AChRs reduce ALP activity in osteoblasts. We used MC3T3-E1 in (A) and
and Mus at various doses (1 nM and 1 lM). (B) Cells were treated with 1 nM ACh in the
CCh. Error bars represent ± S.D. *P < 0.05 as compared with control.3.5. Cholinergic receptors alter their subunits/subtypes during
osteoblastic differentiation
It was previously demonstrated that several factors which pro-
mote neuronal differentiation induce differential regulation of
nAChR subunit expression in neuronal cells [24]. So we examined
the expression of mRNAs for mAChRs and nAChRs in MC3T3-E1
and pOB before and after differentiation induction by RT-PCR. As
shown in Fig. 4G, b4-nAChR mRNA was expressed in pre-osteo-
blasts. After differentiation induction, M1, M2 and M4-mAChRs
and a1, a6, a7, b1, d and e-nAChRs mRNAs were up-regulated
(Fig. 4D–H).
Next, we examined the expression of mRNAs for mAChRs and
nAChRs in MC3T3-E1 and pOB treated with ACh in conditioned
medium. ACh treatment in conditioned medium for 14 days re-
duced the expression of M2 and M4-mAChRs and a6 and a7-nAC-
hRs mRNA compared to the level in the absence of ACh (Fig. 4D–H).
These data indicate that subunits/subtypes of AChRs alter during
osteoblastic differentiation (Fig. 5).
4. Discussion
In this study, we obtained several interesting ﬁndings concern-
ing the relation between osteoblasts and ACh. First, ACh promotes
cell cycle progression in osteoblasts. Second, ACh decreases ALP
activity during osteoblastic differentiation. Third, mature osteo-
blasts express speciﬁc subunits/subtypes of ACh receptor. Finally,
mature osteoblasts express molecules that produce and degrade
ACh during osteoblastic differentiation.le
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Fig. 5. The expression of AChRs during osteoblastic differentiation. Cells stimulated with b-glycerophosphate and ascorbic acid change subunits/subtypes of AChRs and
responsiveness to ACh.
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blasts and differentiated osteoblasts. b4-nAChR was expressed
intensely in pre-osteoblasts. This subunit is widely expressed
in the central and peripheral nervous systems. Within the cen-
tral nervous system, transcripts for b4 subunit expression are re-
stricted [25]. We detected a1, a6, a7, b1, d and e-nAChRs in
differentiated osteoblasts. Interestingly, the a1, b1, d and e sub-
units are expressed in the muscular system but not in the ner-
vous system, whereas the a6 and a7 subunits are expressed in
the nervous system but not in the muscular system [26]. The
nAChRs of mature osteoblasts have properties of the nervous
and muscle systems. M1 and M4-mAChRs expression was
weakly detected in pre-osteoblasts, whereas M1, M2 and M4-
mAChRs expression was strongly detected in differentiated oste-
oblasts. Walker et al. previously demonstrated the presence of
the a4-nAChR subunit in human pOB, and Katono et al. showed
that Nic increased the expression of the a7-nAChR subunit in a
human osteosarcoma cell line [27,28]. We found no expression
of the a4-nAChR subunit in murine osteoblasts, suggesting a
species difference between mice and humans. A number of
researchers have reported the role of a7-nAChR and the M1-
mAChR in cell proliferation [29–31]. Available evidence suggests
that a7-nAChR and M1-mAChR may be involved in the cellular
functions of osteoblasts. In contrast to Nic, ACh did not reduce
mineralization, suggesting that the mAChRs pathway plays a role
in the regulation of mineralization [23].
It seems to be a discrepancy that ACh treatment reduces ALP
expression in osteoblasts while differentiation induction promotes
the secretion of ACh. Here we propose a following model to explain
the phenomena. The action of ACh on osteoblasts changes with
differentiation, since AChRs alter their subunits/subtypes composi-
tion during osteoblastic differentiation. Once ascorbic acid and
b-glycerophosphate promotes differentiation of pre-osteoblastic
cells which express only b4-nAChR, osteoblasts begin to express
M1, M2, M4, a1, a6, a7, b1, d and e-AChRs and produce ACh in
mature phase. In our model, we conjecture that ACh inhibits osteo-
blastic differentiation via b4-nAChR and particular subunits/sub-
types of receptors, i.e., M2, M4, a6 and a7-AChRs, block
inhibitory signaling of differentiation by ACh.Manynon-neuronal cells are equippedwith recyclingpathwayof
ACh [12]. AChE has been found to be essential for osteogenesis as
well as chondrogenesis [32,33]. AChE may play a part not only in
the degradation of ACh, but also in the differentiation of bone and
cartilage during development. We detected a recycling system of
ACh in osteoblasts. While ChAT, CHT1, AChE, and VAChTmRNAs in-
creased during differentiation of murine pOB, only ChAT mRNA in-
creased during differentiation of MC3T3-E1 and AChE and VAChT
mRNA were strongly expressed before differentiation induction in
MC3T3-E1. The reason for this difference is unclear, but we conjec-
ture that cell immortalizationmay be related to the high expression
of these molecules. The synthesis of plasma membrane lipids re-
quires the uptake of choline by choline transporters. CHT1 is a cho-
line transporter expressed by only a few types of non-neuronal
cells [34]. MC3T3-E1 does not express CHT1mRNA, but pOB do. Per-
haps another choline transporter is expressed in MC3T3-E1.
We speculate that ACh plays the following role in osteoblastic
differentiation: the properties of cholinergic receptors change in
pre-osteoblastic cells, increasing the production of ACh during dif-
ferentiation; then ACh acts on pre-osteoblastic cells to promote cell
cycle progression by up-regulating cyclin D1 and decreasing ALP
activity. One nanomole of ACh is sufﬁcient for a pharmacological re-
sponse. Our present results are consistent with the data that ACh in
the nanomolar concentration range act on macrophages [35].
Cholinergic components and AChRs antagonist affect cartilage
and bone metabolism in vivo. In membrane bones of embryonic
chicks paralyzed by the in ovo injection of D-tubocurarine, an
inhibitor of nAChRs, secondary cartilage failed to differentiate
[36]. Moreover, impaired AChE gene expression in thanatophoric
dysplasia, considered one of the most severe forms of chondrodys-
plasia, has been described [32]. These results suggest that choliner-
gic signaling may play a vital role in bone and cartilage metabolism
in vivo. However, bone metabolism has yet to be analyzed in AChR
knockout mice. Whether parasympathetic innervation contributes
to periosteal development is unclear; the parasympathetic nervous
system most likely regulates bone remodeling, but this remains
speculative. Further experiments are necessary to unravel the rela-
tion between the parasympathetic nervous system and bone
remodeling.
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